Overzicht van studies met ultrasound bij prostaatkankerpatiënten welke als operatietechniek net zo effectief is dan standaard chirurgie en/of bestralen maar met veel minder bijwerkingen, zoals incontinentie en impotentie. d.d. 16 april 2004: Zoals eerder gemeld lijkt ultra sound als behandeling bij prostaatkankerpatiënten zonder uitzaaiingen een betere en veiligere optie dan opereren en/of bestralen.

Onderstaand een overzicht van studies die dit bewijzen, gekopieerd van de website van EDAP - The HIFU Company EDAP is an international medical equipment company entirely dedicated to HIFU technology (High Intensity Focused Ultrasound) for the minimally invasive treatment of localized prostate cancer and urological diseases. Op deze website - http://www.edap-tms.com/eng/sitemap.htm staan ook alle persberichten en studies van de afgelopen vijf jaar. Zeer indrukwekkend al moeten we erbij zeggen dat dit natuurlijk wel informatie is die door de producent is gschreven. Maar alles wijst erop dat ultra sound de vervanger gaat worden voor opereren en bestralen bij prostaatkanker, zeker ook omdat bestralen op middellange termijn bij 80% van de behandelde prostaatkankerpatiënten voor problemen zorgt waaronder impotentie en incontinentie. Van een uroloog kregen we nog te horen afgelopen week dat wie een PSA van boven de 20 heeft in ieder geval een verder onderzoek moet ondergaan naar uitzaaiingen in botten en/of lymfklieren. Dan is ultra sound wellicht geen optie, in alle andere gevallen wel lijkt het. Vooraf aan dit algemene studieoverzicht staat het abstract van een studie met ultra sound uitgevoerd tussen 1996 en 1999 bij 559 prostaatkankerpatiënten, met deelname van een Nederlands ziekenhuis en het abstract van de recentste studie uitgevoerd bij 71 prostaatkankerpatiënten met een lokaal recidief. Met zeer opmerkelijke en hoopgevende resultaten. Ook weten we dat bepaalde voeding en voedingssuppletie, waaronder prostasol/PC-Spes een rol kan spelen in het voorkomen en wellicht zelfs genezen van prostaatkanker of recidief ervan. Ons lijkt dat een combinatie van beide een behandeling bij prostaatkanker zou kunnen zijn die wetenschappelijk onderzocht zou moeten worden op resultaat. Wie durft dit op te pakken? Voor informatie over ultra soundtechniek met de HIFU aanpak (High Intensity Focused Ultrasound) kunt u e-mailen met info@edap-hifu.com . Voor adressen van goed gekwalificeerde orthomoleculaire artsen kijk op pagina nuttige adressen. . Bron: website van Edap met grafieken van onderstaande studie enz. From 1995 to 1999, the Company conducted an extensive clinical trial for the Ablatherm in the European Union. The long term patient follow-up is still on-going. This trial, the European Multicentric Study, involved a total of 559 patients suffering from localized prostate cancer and included six sites in France, Germany and The Netherlands. The primary goals of the trial were to assess the safety and effectiveness of the Ablatherm. There are primarily two methods to evaluate the presence of cancerous tissue in the prostate. The first method is based on biopsies. A sextant biopsy is performed inside the prostate to reveal the presence of a tumor. The second method is based on a blood test, the Prostate Specific Antigen ("PSA"), which, although not specific to cancer tumors, measures the proliferation of cells inside the prostate. An interim analysis performed on 559 patients included 402 patients treated with the Ablatherm device as a first-line therapy. Of these patients, 81.4% had a normal PSA and 87.2% had negative biopsies at the last follow-up and were considered as cancer free. The trials also included 157 patients who underwent an Ablatherm treatment as a salvage therapy after a previous failed therapy (hormonotherapy, radiation or prostatectomy). Of these patients, 80.7% and 67.9% had negative biopsies and normal PSA after treatment, respectively. Based on these results, the Company obtained, in January 2000, the CE Mark which allows the Company to market the Ablatherm in the European Union. In February 2001, the French Urology Association ("AFU") began an independent clinical trial in order to confirm the efficacy and safety results observed in the European Multicentric Study, and to evaluate the therapy related costs. Patient recruitment was successfully performed at eight investigational sites, six of which used a mobile machine. Patient enrolment was completed in a 11-month period with 117 patients included. Patient follow-up is planned for two years, with intermediate assessment at one year (end of 2003). Urology. 2004 Apr;63(4):625-9. Meest recente studie is deze studie van ultra sound bij een lokaal recidief van prostaatkanker uitgevoerd bij 71 patiënten, ook met de HIFU techniek. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Gelet A, Chapelon JY, Poissonnier L, Bouvier R, Rouviere O, Curiel L, Janier M, Vallancien G. Department of Urology, Edouard Herriot Hospital, Lyon, France. OBJECTIVES: To evaluate the efficacy and safety of a salvage therapy using transrectal high-intensity focused ultrasonography (HIFU) for locally recurrent prostate cancer after external beam radiotherapy. METHODS: All patients were treated with HIFU under general or spinal anesthesia. Specific parameters were progressively defined to avoid any rectal damage. Patient follow-up included sextant biopsy and prostate-specific antigen (PSA) measurement. RESULTS: A total of 71 patients were included in this series. The main baseline characteristics before HIFU were mean age 67 +/- 5.86 years, mean prostate volume 21.4 +/- 11.1 cm(3), and mean PSA level 7.73 +/- 8.10 ng/mL. All biopsies were positive, with a pre-HIFU Gleason score of 2 to 6 in 24 patients, 7 in 13 patients, and 8 to 10 in 34 patients. The mean patient follow-up was 14.8 months (range 6 to 86). After HIFU treatment, 57 (80%) of the 71 patients had negative biopsies, and 43 (61%) of 71 had a nadir PSA level of less than 0.5 ng/mL. The nadir level was obtained within 3 months. At the last follow-up, 44% of the patients had no evidence of any disease progression. The adverse events related to HIFU included rectourethral fistula in 6%, grade 3 incontinence in 7%, and bladder neck stenosis in 17%. No rectal injury occurred with the use of specific parameters. CONCLUSIONS: HIFU appears to be a promising treatment option with a curative chance for patients with local recurrence after external beam radiotherapy. The HIFU-related morbidity was lower than the morbidity reported after other types of salvage therapy, leading to a favorable risk/benefit ratio. PMID: 15072864 [PubMed - in process] Algemeen overzicht studies met ultra sound bij prostaatkankerpatiënten: 5 Year Experience with High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer A. Blana, B. Walter, S. Rogenhofer, W.F. Wieland, Regensburg, Germany. WCE Congress Abstract, Montréal, Canada, 2003 • Could High Intensity Focused Ultrasound be an Alternative Treatment Option in the Treatment of Local Recurrence Prostate Cancer? S. Rogenhofer, B. Walter, A. Blana, W.F. Wieland, Regensburg, Germany. WCE Congress Abstract, Montréal, Canada, 2003 • HIFU and Localized Prostate Cancer: Efficacy Results from the European Multicentric Study – An Update Ch. Chaussy, S. Thüroff, Munich, Germany. WCE Congress Abstract, Montréal, Canada, 2003 • The Current Status of High Intensity Focused Ultrasound (HIFU) in the treatment of Localized Prostate Cancer and the Impact of a Combined Resection Ch. Chaussy, S. Thüroff, Munich, Germany. WCE Congress Abstract, Montréal, Canada, 2003 • Local Bioptic Histopathological Efficacy of High Intensity Focused Ultrasound (HIFU) at 3 MHz S. Thüroff, Ch. Chaussy, Munich, Germany. WCE Congress Abstract, Montréal, Canada, 2003 • Is Diagnostic Transurethral Prostate Resection (TURP) a Valid Diagnostic Tool for Prostatic Cancer Detection? S. Thüroff, Ch. Chaussy, Munich, Germany. WCE Congress Abstract, Montréal, Canada, 2003 • High Intensity Focused Ultrasound (HIFU) in Locally Advanced Prostate Cancer S. Thüroff, Ch. Chaussy, Munich, Germany. WCE Congress Abstract, Montréal, Canada, 2003 • Prostate Cancer Control with Transrectal HIFU in 245 Consecutive Patients A. Gelet, J.Y. Chapelon1, L. Poissonnier, R. Bouvier, O. Rouvière, I. Bah-Clozel, D. Lyonnet, J.M. Dubernard, Edouard Herriot Hospital, Dept. Of Urology, Lyon, France, INSERM Unit 556, Lyon, France. WCE Congress Abstract, Montréal, Canada, 2003 • Salvage Therapy of Prostate Cancer with High Intensity Focused Ultrasound after Radiation Failure A. Gelet, J.Y. Chapelon1, R. Bouvier, O. Rouvière, L. Poissonnier, J.M. Marechal, J.M. Dubernard, Edouard Herriot Hospital, Dept. Of Urology, Lyon, France, 1INSERM Unit 556, Lyon, France. WCE Congress Abstract, Montréal, Canada, 2003 • High Intensity Focused Ultrasound : Minimal Invasive Transrectal Treatment for Localized Prostate Cancer. 2 Years – 200 Patients. C. D’Hont, M. Lantsoght, P. Van Erps, Antwerp, Belgium. WCE Congress Abstract, Montréal, Canada, 2003 • Experiences with 3MHz HIFU Treatment of Localized Prostate Cancer in 576 Patients: the Munich Study S. Thüroff, Ch. Chaussy, H.J. Kiel, Munich, Germany. AUA Congress Abstract, Chicago, USA, 2003 • Transurethral Resection Combined with High Intensity Focused Ultrasound (HIFU) : Increased Effectivity and Decreased Side Effects in the Treatment of Localized Prostate Cancer Ch. Chaussy, S. Thüroff, H.J. Kiel, Munich, Germany. AUA Congress Abstract, Chicago, USA, 2003 • High Intensity Focused Ultrasound (HIFU) Treatment for Localized Prostate Cancer : French Urological Association Multicentric Study – First Results on 117 Patients P. Conort, Paris, France; P. Rischmann, Toulouse, France; D. Chevalier, Nice, France; Ch. Saussine, Strasbourg, France; G. Vallancien, Paris, France; H. Bensadoun, Caen, France; Ch. Pfister, Rouen, France, A. Gelet, Lyon, France AUA Congress Abstract, Chicago, USA, 2003 • High Intensity Focused Ultrasound (HIFU) and Neoadjuvant Transurethral Resection Ch. Chaussy, S. Thüroff, H.J. Kiel, Munich, Germany. EAU Congress Abstract, Madrid, Spain, 2003 • Transrectal Focused Ultrasound (HIFU) in Prostate Cancer S. Thüroff, Ch. Chaussy, H.J. Kiel, Munich, Germany. EAU Congress Abstract, Madrid, Spain, 2003 • Transrectal Focused Ultrasound and Localized Prostate Cancer: May the Nadir PSA predict the Treatment Success? A. Gelet, Edouard Herriot Hospital, Dept. Of Urology, Lyon, France, J.Y. Chapelon, INSERM Unit 556, Lyon, France, R. Bouvier, Edouard Herriot Hospital, Dept. Of Anatomopathology, Lyon, France, O. Rouvière, Edouard Herriot Hospital, Dept. Of Radiology, Lyon, France, M. Colombel, Edouard Herriot Hospital, Dept. Of Urology, Lyon, France, J. Dubernard, Edouard Herriot Hospital, Dept. Of Urology, Lyon, France EAU Congress Abstract, Madrid, Spain, 2003 • High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer G. Conti, A. Paulesu, R. Nespoli, V. Lancini, G. Comeri, St Anna Hospital, Dept. Of Urology, Como, Italy EAU Congress Abstract, Madrid, Spain, 2003 • Non-Invasive Treatment of Localized Prostate Cancer by Transrectal High Intensity Focused Ultrasound A. Blana, B. Walter, W.F. Wieland, St Josef Hospital, Dept. of Urology, Regensburg, Germany. WCE Congress Abstract, Genoa, Italy, 2002 • HIFU for the Treatment of Prostate Cancer: Safety and Efficacy Results of the First Belgian Experience M. Lantsoght, C. D’Hont, M. Sorber, E. de Smedt, J. Cortvriend, P. Van Erps, AZ Middelheim, Dept. of Urology, Antwerp, Belgium. SIU Congress Abstract, Stockholm, Sweden, 2002 • High Intensity Focused Ultrasound (HIFU) for Localized Prostate Cancer: The Italian Experience G. Conti, A. Paulesu, G.C. Comeri, St Anna Hospital, Dept. Of Urology and Andrology, Como, Italy. SIU Congress Abstract, Stockholm, Sweden, 2002 • Ultrasons Focalisés et Récurrence Locale du Cancer de la Prostate après Radiothérapie Externe G. Vallancien, X. Cathelineau, D. Prapotnich, S. Gibert, H. Baumert, B. Guillonneau, Institut Mutualiste Montsouris, Paris, France. AFU Congress Abstract, Paris, France, 2002 • Traitement du Cancer Prostatique (CP) Localisé par Ultrasons Focalisés de Haute Intensité (HIFU) : Etude multicentrique sur 117 patients. Résultats à 6 Mois. P. Conort, P. Rischmann, D. Chevallier, C. Saussine, G. Vallancien, Ch. Pfister, H. Bensadoun, J. Amiel, Ph. Grise, P. Coloby, F. Richard, A. Gelet AFU Congress Abstract, Paris, France, 2002 • High Intensity Ultrasound (HIFU) and Adjuvant Transurethral Resection (TURP) - Experience with over 100 cases C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. EAU Congress Abstract, Birmingham, England, 2002 • PSA Stability After High Intensity Focused Ultrasound (HIFU) in Prostate Cancer C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. AUA Congress Abstract, Orlando, USA, 2002 • Long Term Outcome after High Intensity Focused Ultrasound (HIFU) Therapy for Localized Prostate Cancer A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France AUA Congress Abstract, Orlando, USA, 2002 • Traitement du Cancer Localisé de la Prostate par Ultrasons Focalisés de Haute Intensité (HIFU) Associé à la Résection Endoscopique de la Prostate (TURP) C. Jayet, B. Guillonneau, G. Vallancien, Institut Mutualiste Montsouris, Paris, France. AFU Congress Abstract, Paris, France, 2001 • Cancer Localisé de la Prostate avec PSA <= 10 ng/ml : Efficacité du Traitement par Ultrasons Focalisés Transrectaux A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, D. Lyonnet, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France. AFU Congress Abstract, Paris, France, 2001 • High Intensity Ultrasound (HIFU) in Locally Advanced Prostate Cancer C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. AUA Congress Abstract, Anaheim, USA, 2001 • HIFU for the Treatment of Localized Prostate Cancer: Efficacy Results of the European Multicentric Study C. Chaussy, S. Thüroff, G. Vallancien, W. Wieland, H.J. Kiel, A. Le Duc, F. Desgranchamps, J. de la Rosette, A. Gelet, European Ablatherm Study Group. AUA Congress Abstract, Anaheim, USA, 2001 • Prostate Cancer: Salvage Therapy with High Intensity Focused Ultrasound (HIFU) after Radiation Failure A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, M. Colombel, J.M. Maréchal J.M. Dubernard. Edouard Herriot Hospital, Lyon, France. EAU Congress Abstract, Geneva, Switzerland, 2001 • Localized Prostate Cancer: Efficacy of the Transrectal High Intensity Focused Ultrasound (HIFU) Treatment A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, D. Lyonnet, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France. WCE Congress Abstract, 2000 • Localized Prostate Cancer (PCA) Treated with High Intensive Focused Ultrasound (HIFU) C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. AUA Congress Abstract, Atlanta, USA, 2000 • Local Recurrency of Prostate Cancer (rPCa) Treated by Focused Ultrasound (HIFU) C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. SIU Congress Abstract, Singapore, 2000 • Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer: Energy Efficacy Correlation C. Chaussy, S. Thüroff, R. Zimmermann, A. Gelet. Edouard Herriot Hospital, Lyon and Munich-Harlaching University, Germany. SIU Congress Abstract, Singapore, 2000 • Prostate Cancer Treated with HIFU: Long Term Results A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière,, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France. SIU Congress Abstract, Singapore, 2000 • Focused Ultrasound (HIFU) in Prostate Cancer: The Influence of Inclusion Criteria on Results C. Chaussy, S. Thüroff, R. Zimmermann, Munich-Harlaching University, Germany. SIU Congress Abstract, Singapore, 2000 • Focused Ultrasound (HIFU) for Prostate Cancer: Technical and Applicative Progress C. Chaussy, S. Thüroff, R. Zimmermann, Munich-Harlaching University, Germany. SIU Congress Abstract, Singapore, 2000 • Cancer Localisé de la Prostate; Efficacité du Traitement par Ultrasons Focalisés Transrectaux A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière,, D. Lyonnet, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France. AFU Congress Abstract, Paris, France, 2000 • Traitement des Cancers Prostatiques par Ultrasons Focalisés: Evaluation par IRM de la Zone de Nécrose A. Gelet, A. Raudrant, R. Bouvier, O. Rouvière, D. Lyonnet, Edouard Herriot Hospital, Lyon, France. AFU Congress Abstract, Paris, France, 2000 • High Intensity Focused Ultrasound (HIFU) Followed after 7-12 Days by Radical Retropubic Prostatectomy in Patients with Localized Prostate Carcinoma H. Beerlage, G. Van Leenders, G. Oosterhof, F. Debruyne, J. de la Rosette, Department of Urology, Nijmegen, The Netherlands. EAU Congress Abstract, Stockholm, Sweden, 1999 • 3D-Contrast Ultrasonography of the Prostate: HIFU Defect in Doppler Imaging Correlated to Pathology H. Beerlage, R. Aarnink, G. Van Leenders, H. Wijkstra, F. Debruyne, J. de la Rosette, Department of Urology, Nijmegen, The Netherlands. WCE Congress Abstract, Rodos, Greece, 1999 • Transrectal High Intensive Ultrasound (HIFU) in Localized Prostate Cancer: Partial or Total Treatment C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. WCE Congress Abstract, Rodos, Greece, 1999 ARTICLES • The Status of High-Intensity Focused Ultrasound in the Treatment of Localized Prostate Cancer and the Impact of a Combined Resection C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. Current Urology Reports, Volume 4, Issue 3, 2003 • Résultats du traitement par ultrasons focalisés transrectaux du cancer localisé de la prostate (120 patients avec PSA < à 10ng/ml) L. Poissonnier (1), A. Gelet (1), J.Y. Chapelon (2), R. Bouvier (1), O. Rouvière (1), C. Pangaud(1), D. Lyonnet (1), J.M. Dubernard(1). Edouard Herriot Hospital, Lyon, France (1) – INSERM Unit 556, Lyon, France (2). Progrès en Urologie, Volume 13, Number 1, February 2003 • Transrectal High-Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Factors Influencing the Outcome A. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, D. Lyonnet, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France. European Urology, 2001;40:124-129 • Transrectal High-Intensity Focused Ultrasound: Minimally Invasive Therapy of Localized Prostate Cancer B. Gelet, J.Y. Chapelon, R. Bouvier, O. Rouvière, Y. Lasne, D. Lyonnet, J.M. Dubernard. Edouard Herriot Hospital, Lyon, France. Journal of Endourology, Volume 14, Number 6, August 2000 • High-Intensity Focused Ultrasound: Complications and Adverse Event C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. Molecular Urology, Volume 4, Number 3, 2000 • High-Intensity Focused Ultrasound in Prostate Cancer: Results after 3 Years C. Chaussy, S. Thüroff, Munich-Harlaching University, Germany. Molecular Urology, Volume 4, Number 3, 2000 • Local Control of Prostate Cancer by Transrectal High Intensity Focused Ultrasound Therapy : Preliminary Results A. Gelet, J.Y. Chapelon, R. Bouvier, C. Pangaud, Y. Lasne. The Journal of Urology, Vol. 161, 156-162, January 1999. • Treatment of Localized Disease High Intensity Focused Ultrasound (HIFU) P. Teillac, J. Adolfsson, S. Arap, J. de la Rosette, F. Eschwege; T. Flam, J. Gillenwater, K. Hanash, T. Kakizoe, F. Keuppens, T. Loch, H. Ragde, F. Richard, P. Scardino, J. Schmidt, G. Stock, N. Stone, G. Vallancien. Prostate Cancer - 2nd International Consultation on Prostate Cancer - June 27-29, 1999, Paris • Influence of High-Intensity Focused Ultrasound on the Development of Metastase G. Oosterhof, E. Cornel, G. Smits, F. Debruyne, J.A. Schalken. European Urology, 32 : 91-95, January 1997.

prostaatkanker


Plaats een reactie ...

Reageer op "HIFU (High Intensity Focused Ultrasound): Overzicht van studies met ultrasound bij prostaatkankerpatiënten welke als operatietechniek net zo effectief is dan standaard chirurgie en/of bestralen maar met veel minder incontinentie en impotentie"


Gerelateerde artikelen
 

Gerelateerde artikelen

HIFU - High-Intensity Focused >> High Intensity Focused Ultrasound >> HIFU - High Intensity Focused >> HIFU - High Intensity Focused >> HIFU - Ultrasound als operatietechniek >> HIFU (High Intensity Focused >> Nederlandstalig artikel over >> HIFU - High Intensity Focused >>